Safinamide Mesilate
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Parkinson Disease
Conditions
Parkinson Disease
Trial Timeline
Apr 5, 2022 → May 25, 2023
NCT ID
NCT05312632About Safinamide Mesilate
Safinamide Mesilate is a approved stage product being developed by Eisai for Parkinson Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT05312632. Target conditions include Parkinson Disease.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05312632 | Approved | Completed |
Competing Products
20 competing products in Parkinson Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| UB-312 + Placebo | Vaxxinity | Phase 1 | 25 |
| NAV5001 + DaTscan | Navidea Biopharmaceuticals | Phase 3 | 69 |
| exidavnemab + Placebo Comparator | BioArctic AB | Phase 2 | 49 |
| LY4006896 + Placebo | Eli Lilly | Phase 1 | 33 |
| ATH-1017 + Placebo | LeonaBio | Phase 2 | 44 |
| piclozotan + 0.9% sodium chloride (normal saline) | Daiichi Sankyo | Phase 2 | 52 |
| Mirabegron + Placebo | Astellas Pharma | Approved | 85 |
| E2007 | Eisai | Phase 3 | 77 |
| ARICEPT | Eisai | Phase 3 | 77 |
| Perampanel | Eisai | Phase 3 | 77 |
| GPI 1485 | Eisai | Phase 2 | 52 |
| E2007 | Eisai | Phase 3 | 77 |
| Prior Donepezil 5mg + Prior Donzepezil 10mg + Prior Placebo | Eisai | Phase 3 | 77 |
| Equfina 50 mg | Eisai | Pre-clinical | 23 |
| Equfina | Eisai | Pre-clinical | 23 |
| perampanel + placebo | Eisai | Phase 2 | 52 |
| Lemborexant + placebo | Eisai | Approved | 85 |
| Placebo + E2007 + E2007 | Eisai | Phase 3 | 77 |
| E2007 + E2007 + E2007 | Eisai | Phase 2 | 52 |
| E2007 | Eisai | Phase 2 | 52 |